83B Stock Chart & Stats
€1.85
€0.10(5.09%)
At close: 4:00 PM EDT
€1.85
€0.10(5.09%)
Day’s Range― - ―
52-Week Range€1.63 - €3.78
Previous CloseN/A
Volume505.00
Average Volume (3M)48.00
Market Cap
€4.44B
Enterprise Value€28.64K
Total Cash (Recent Filing)€19.73B
Total Debt (Recent Filing)€2.62B
Price to Earnings (P/E)4.0
Beta0.61
Next Earnings
Mar 30, 2027EPS Estimate
0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.44
Shares Outstanding2,538,264,400
10 Day Avg. Volume0
30 Day Avg. Volume48
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.97
Price to Sales (P/S)3.03
P/FCF Ratio5.87
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€3.26Price Target Upside76.03% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)0.11
Revenue Forecast (FY)€1.03B
Bulls Say, Bears Say
Bulls Say
Revenue And Profit ExpansionThe sharp 2025 increase in revenue and profitability indicates strong commercial momentum across the company’s marketed therapies. If the expanded earnings base persists, it can provide greater funding for product development, commercialization, and future growth while strengthening operating scale.
Conservative Balance SheetMaterially lower leverage improves financial resilience and gives 3SBio more flexibility to invest in its biopharmaceutical portfolio without relying heavily on borrowing. Expanded assets and equity also support a stronger platform for scaling operations and absorbing business volatility.
Strong Cash GenerationFree cash flow closely tracking net income supports the quality of reported earnings and demonstrates meaningful internal cash generation. This strengthens the company’s ability to fund research, manufacturing, commercialization, and other strategic priorities while limiting dependence on external capital.
Bears Say
Earnings Sustainability RiskThe unusually strong 2025 results have not yet been demonstrated consistently across the broader historical period. Earlier variability in growth and profitability makes forward earnings power less predictable and creates a durable risk that recent performance may moderate as comparisons normalize.
Margin VolatilityLarge swings in net margin indicate that profitability has not followed a stable multi-year trajectory. Even with exceptional 2025 margins, this variability complicates planning and raises the risk that earnings quality and operating profitability could retreat if the factors behind the latest improvement do not persist.
Uneven Cash ConversionPrior periods of weaker cash conversion show that accounting earnings have not always translated into cash at a consistent rate. This can constrain internally funded investment during weaker years and makes the durability of the latest cash-flow improvement important to monitor over coming quarters.
3SBio News
83B FAQ
What was 3SBio’s price range in the past 12 months?
3SBio lowest stock price was €1.63 and its highest was €3.78 in the past 12 months.
What is 3SBio’s market cap?
3SBio’s market cap is €4.44B.
When is 3SBio’s upcoming earnings report date?
3SBio’s upcoming earnings report date is Mar 30, 2027 which is in 190 days.
How were 3SBio’s earnings last quarter?
3SBio released its earnings results on Aug 20, 2026. The company reported €0.056 earnings per share for the quarter, missing the consensus estimate of €0.082 by -€0.026.
Is 3SBio overvalued?
According to Wall Street analysts 3SBio’s price is currently Undervalued.
Does 3SBio pay dividends?
3SBio does not currently pay dividends.
What is 3SBio’s EPS estimate?
3SBio’s EPS estimate is 0.06.
How many shares outstanding does 3SBio have?
3SBio has 2,538,264,400 shares outstanding.
What happened to 3SBio’s price movement after its last earnings report?
3SBio reported an EPS of €0.056 in its last earnings report, missing expectations of €0.082. Following the earnings report the stock price went down -6.541%.
Which hedge fund is a major shareholder of 3SBio?
Currently, no hedge funds are holding shares in DE:83B
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
3SBio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€3.26 (76.03% Upside)
€3.26 (76.03% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-50.50%
12-Months-Change
Fundamentals
Return on Equity
1.55%
Trailing 12-Months
Asset Growth
57.66%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
3SBio
Operating as an investment holding company, 3SBio Inc. specializes in the full lifecycle of biopharmaceutical products within the People's Republic of China, encompassing research, development, manufacturing, marketing, and sales. Its diverse portfolio addresses a range of medical needs. Key therapeutic agents include TPIAO, a recombinant human thrombopoietin for chemotherapy-induced and immune thrombocytopenia; YISAIPU, a tumor necrosis factor for rheumatoid arthritis, ankylosing spondylitis, and psoriasis; and recombinant human erythropoietins EPIAO and SEPO, along with Aiyishu, to combat various forms of anemia. In oncology, Cipterbin is used for HER2-positive metastatic breast cancer in combination with chemotherapy. Intefen, a recombinant human interferon, targets lymphatic or hematopoietic malignancies and viral infections, while Inleusin, a human interleukin-2, treats renal cell carcinoma, melanoma, and thoracic fluid build-up. The company also offers Mandi for male alopecia and alopecia areata; Xenopax to prevent acute rejection post-renal transplant; Byetta for glycemic control in type 2 diabetes patients; and Qiming Keli for retinopathy linked to type 2 diabetes. SPARIN, an injectable low-molecular-weight heparin calcium, serves in the prophylaxis and treatment of deep vein thrombosis, and prevents clotting during hemodialysis. Beyond its core pharmaceutical activities, 3SBio Inc. provides additional services such as trading, project management and consultation, technology, and agricultural support. The company maintains strategic alliances with numerous prominent organizations, including AstraZeneca, Lilly, Toray Industries Inc, Samsung Bioepis, Refuge Biotechnologies, Verseau, TLC, Numab, GenSight, Sensorion, and the Dana–Farber Cancer Institute. Established in 1993, its headquarters are situated in Shenyang, People's Republic of China.
83B Stock 12 Month Forecast
Average Price Target
€3.26
▲(76.03% Upside)
Technical Analysis
Wuxi Biologics (Cayman)
―
Akeso, Inc.
―
RemeGen Co. Ltd. Class H
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Shanghai Henlius Biotech, Inc. Class H
―